Vineti, Inc., a San Francisco, CA-based software automation and analytics platform for cell and gene therapies, closed a $33.5m in Series B funding.
The round was led by Canaan and DFJ, with participation from GE Ventures, Section 32, Casdin Capital, and LifeForce Capital, Mayo Clinic Ventures, along with other undisclosed investors. In conjunction with the funding, Nina Kjellson, General Partner at Canaan, and Michael Pellini, M.D., Managing Partner at Section 32 and Chairman of Foundation Medicine, Inc., will join Vineti’s Board of Directors.
The company intends to use the funds to extend its technology platform for individualized therapies and expand into Europe and Asia-Pacific.
Led by Amy DuRoss, CEO and co-founder, Vineti provides a cloud-based platform of record (integrates logistics, manufacturing and clinical data) for individualized therapies to align and orchestrate the cell and gene therapy process and improve product performance overall. The configurable software automates, orchestrates, and simplifies the complex workflows behind personalized therapies, and allows pharmaceutical partners to address emerging opportunities and challenges as these therapies move into mainstream medicine.
The platform also enables integrations with other parts of the therapy ecosystem.